7 and 14 Thus, tools with greater dissemination, such as find protocol PAQLQ, PedsQL-Asthma, and DISABKIDS, have versions and cultural adaptations in several languages, contributing even more to their prevalence in literature. Few data are available on the integration of these instrument in clinical practice and strategies necessary for the best use of these tools in the long-term

monitoring of children. In Brazil, PAQLQ is the only tool with complete validation (cultural adaptation). The linguistic validation was performed in 2001, and only recently was the cultural validation of this version completed, showing good psychometric properties.38 Regarding the limitations of this systematic review, it is noteworthy that original articles published in languages other than English, Spanish and Portuguese were not included in the search. However, among the tools identified, some were found to have been originally developed in languages other than English, the language in which the results were published. Considering that English is the predominant language in health sciences, it is believed that few tools were out of the present systematic review. As a possible expression of this situation, a recent study

Ibrutinib mouse assessed the HRQoL tools available in Latin American countries between 2000-2010, for children and adolescents.13 Of 31 tools, among specific and generic, only PAQLQ was available and had had cultural adaptations in several countries. In conclusion, there are many specific questionnaires to assess HRQoL of children and adolescents diagnosed with asthma. Of these, the three most frequently used are the PAQLQ, the PedsQL-Asthma, and DISABDKIDS, while other questionnaires have had few publications, suggesting limited use. Only one tool has been validated in Brazil. The choice of an HRQoL

instrument requires attention regarding its original psychometric properties, but also requires the feasibility study of its second adaptation, through consideration the cultural elements present in its creation.4 and 14 CNPq, CAPES, FAPERGS. The authors declare no conflicts of interest. “
“Persistent pulmonary hypertension of the newborn (PPHN) is a syndrome that, although recognized for over 30 years, continues to challenge physicians, and little is known about its etiology, pathogenesis, and prevention. With the exception of inhaled nitric oxide (NO), treatment is limited and the use of new drugs is based solely on experimental evidence, or in the treatment of adults with primary pulmonary hypertension. The clinical features of the syndrome and its general and specific treatment were reviewed in the present study. For a better understanding of its pathogenesis and the use of certain pharmacological interventions, an overview of the factors responsible for the control of pulmonary vascular tone and hemodynamic alterations during the transition from fetal to postnatal life is necessary.